Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Reichetzeder

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Pharmacology|April 20, 2017
Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injuryChristoph Reichetzeder, Karoline von Websky, Oleg Tsuprykov, et al.
Journal of Hypertension|July 1, 2014
Fetal and maternal angiotensin (1-7) are associated with preterm birthYou-Peng Chen, Yong-Ping Lu, Jian Li, et al.
Epigenetics|May 14, 2016
Maternal eNOS deficiency determines a fatty liver phenotype of the offspring in a sex dependent mannerBerthold Hocher, Hannah Haumann, Jan Rahnenführer, et al.
American Journal of Physiology. Cell Physiology|March 20, 2025
Effects of high salt intake on glucose metabolism, liver function, and the microbiome in rats: influence of ACE inhibitors and angiotensin II receptor blockersXiaoli Zhang, Mohamed M S Gaballa, Ahmed A Hasan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 29, 2025
Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5/6 nephrectomyXin Chen, Christian T Wohnhaas, Denis Delić, et al.
Kidney International|April 17, 2016
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomyOleg Tsuprykov, Ryotaro Ando, Christoph Reichetzeder, et al.
Journal of Cellular and Molecular Medicine|September 22, 2025
Reduced FGF9 Leads to Kidney Injury Through Regulating Renal Tubular Epithelial Cell EMT in DiabetesWen-Qing Chen, Chengyang Sun, Xiaotan Zhang, et al.
Diabetologia|May 20, 2018
Folate treatment of pregnant rat dams abolishes metabolic effects in female offspring induced by a paternal pre-conception unhealthy dietJian Li, Yong-Ping Lu, Oleg Tsuprykov, et al.
American Journal of Physiology. Cell Physiology|February 13, 2023
Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement systemXin Chen, Denis Delić, Yaochen Cao, et al.
American Journal of Physiology. Cell Physiology|August 26, 2024
Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axisLei Lei, Ting Zhu, Tian-Jiao Cui, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Pharmacology|April 20, 2017
Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injuryChristoph Reichetzeder, Karoline von Websky, Oleg Tsuprykov, et al.
Journal of Hypertension|July 1, 2014
Fetal and maternal angiotensin (1-7) are associated with preterm birthYou-Peng Chen, Yong-Ping Lu, Jian Li, et al.
Epigenetics|May 14, 2016
Maternal eNOS deficiency determines a fatty liver phenotype of the offspring in a sex dependent mannerBerthold Hocher, Hannah Haumann, Jan Rahnenführer, et al.
American Journal of Physiology. Cell Physiology|March 20, 2025
Effects of high salt intake on glucose metabolism, liver function, and the microbiome in rats: influence of ACE inhibitors and angiotensin II receptor blockersXiaoli Zhang, Mohamed M S Gaballa, Ahmed A Hasan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 29, 2025
Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5/6 nephrectomyXin Chen, Christian T Wohnhaas, Denis Delić, et al.
Kidney International|April 17, 2016
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomyOleg Tsuprykov, Ryotaro Ando, Christoph Reichetzeder, et al.
Journal of Cellular and Molecular Medicine|September 22, 2025
Reduced FGF9 Leads to Kidney Injury Through Regulating Renal Tubular Epithelial Cell EMT in DiabetesWen-Qing Chen, Chengyang Sun, Xiaotan Zhang, et al.
Diabetologia|May 20, 2018
Folate treatment of pregnant rat dams abolishes metabolic effects in female offspring induced by a paternal pre-conception unhealthy dietJian Li, Yong-Ping Lu, Oleg Tsuprykov, et al.
American Journal of Physiology. Cell Physiology|February 13, 2023
Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement systemXin Chen, Denis Delić, Yaochen Cao, et al.
American Journal of Physiology. Cell Physiology|August 26, 2024
Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axisLei Lei, Ting Zhu, Tian-Jiao Cui, et al.
Pageof 7